You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

VIRACEPT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Viracept patents expire, and what generic alternatives are available?

Viracept is a drug marketed by Agouron Pharms and is included in three NDAs.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Drug patent expirations by year for VIRACEPT
Drug Prices for VIRACEPT

See drug prices for VIRACEPT

Recent Clinical Trials for VIRACEPT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 1
Joseph Anthony Lucci IIIPhase 2
The University of Texas Health Science Center, HoustonPhase 2

See all VIRACEPT clinical trials

Pharmacology for VIRACEPT

US Patents and Regulatory Information for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ⤷  Try a Trial ⤷  Try a Trial
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIRACEPT

See the table below for patents covering VIRACEPT around the world.

Country Patent Number Title Estimated Expiration
Hungary T75652 ⤷  Try a Trial
Slovenia 722439 ⤷  Try a Trial
Slovakia 43996 HIV-PROTEASE INHIBITORS ⤷  Try a Trial
European Patent Office 0889036 Inhibiteurs de protease HIV (HIV protease inhibitors) ⤷  Try a Trial
Poland 185647 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.